Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast

López-Bonet, Eugeni; Pérez-Martínez, Maria Carmen; Martin-Castillo, Begofia; Alonso-Ruano, Miguel; Tuca, Francesc; Oliveras‐Ferraros, Cristina; Cufí, Sílvia; Vázquez-Martín, Alejandro; Beltran, M.; Bernadó, Luis; Menendez, Javier A.

doi:10.1007/s10549-010-1229-9

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies suggest mammaglobin and GCDFP‐15 as markers useful in distinguishing a NEBC metastasis from a NET metastasis [14, 21, 22]. It is possible that the constant development of new methods and the subsequent change of NET guidelines over the years may cause lack of satisfactory coverage of the relevant immunohistochemical analyses in retrospective descriptive studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metastases from Neuroendocrine Tumors to the Breast Are More Common than Previously Thought. A Diagnostic Pitfall?

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Patients with breast tumors presumed to be mammary carcinoma with neuroendocrine differentiation but showing no expression of progesterone and estrogen receptors should be further investigated for the presence of a primary NET. [4, 6-9, 13, 16, 18, 23-31], NEBC [21,22,[32][33][34][35][36][37]…”

Section: Discussionmentioning

confidence: 99%

Metastases from Neuroendocrine Tumors to the Breast Are More Common than Previously Thought. A Diagnostic Pitfall?

et al. 2013

View full text Add to dashboard Cite

show abstract

“…WHO criteria for neuroendocrine breast carcinoma are given as follows: the presence of 50% tumour immunoreactivity for one of three neuroendocrine markers, including chromogranin A, synaptophysin and CD56 3 5. All neuroendocrine breast carcinomas expressed high levels of ERs and PRs 6. Her-2/neu has commonly been reported to be negative in neuroendocrine breast carcinomas 7…”

Section: Discussionmentioning

confidence: 99%

Cytokeratin 7 negative invasive breast carcinoma: clinicopathological and immunohistochemical analysis of 14 cases with clinical follow-up

Moatamed

Sarah

et al. 2015

J Clin Pathol

View full text Add to dashboard Cite

Cytokeratin 7 (CK 7) negative breast tumours are reported to occur rarely. We studied 14 CK 7 negative cases of primary invasive ductal carcinoma (IDC) detected during sentinel lymph node metastases work-up and immunohistochemistry panel in the work-up of metastatic carcinoma of unknown origin. Axillary lymph node metastases were present in seven patients (50%). Oestrogen receptor (ER) was strongly positive in all cases: progesterone receptor in 78%, Her-2/neu in 7% and high proliferation index with Ki-67 >20% was seen in 71% of the cases. Metastatic and/or recurrence were found in 8 of 14 patients (57%) with the mean clinical follow-up of 55 months. Metastatic sites include multiple bones, brain, spinal cord, liver, pancreas, ovary, lung, lymph node other than ipsilateral axillary and skin. 12 of 14 patients received adjuvant chemotherapy. All 14 patients received hormonal therapy and radiation therapy. Morphologically, IDC with neuroendocrine features was noted in 57%. Synaptophysin stain was positive in 57% and chromogranin was positive in 21% of the cases. In conclusion, these CK 7 negative breast carcinomas were ER positive, mostly Her-2/neu negative, had high Ki-67 and frequently showed neuroendocrine differentiation. More than half of these cases had a poor outcome.

show abstract

“…Отмечено, что оценка уровня маммоглобина может применяться для скрининга и выявления первичного или метаста-тического РМЖ, прогнозирования заболеваемости и излеченности пациенток. Исследования продолжа-ются [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31].…”

Section: актуальная темаunclassified

Treatment of patients with bone marrow metastases: the present state of the problem

Козловская¹,

Antonenkova²,

Zhavrid³

2016

Tumors of female reproductive system

View full text Add to dashboard Cite

12М а м м о л о г и я / M a m m o l o g y 1 ' 2 0 1 6 Том 12 / Vol. 12 88.7 and 69.3 %, respectively (p < 0.01). ОПУХОЛИ ЖЕНСКОЙ РЕПРОДУКТИВНОЙ СИСТЕМЫ TUMORS OF FEMALE REPRODUCTIVE SYSTEM Key words: breast cancer, micrometastases, tumor cells in bone marrow, polymerase chain reactionРак молочной железы (РМЖ) представляет собой патогенетически полиморфное заболевание, поэтому все пациентки не могут получать одинаковое лечение с одинаковым эффектом. Несмотря на достигнутые результаты в ранней диагностике и успехи в комплекс-ной терапии (хирургическое лечение, послеопераци-онная лучевая и химиотерапия (ХТ)), безрецидивная выживаемость ограничена из-за возникновения отда-ленных метастазов, которые являются основной при-чиной смерти этой категории пациенток.По данным канцер-регистра Республики Беларусь, за 2014 г. зарегистрировано 3835 новых случаев РМЖ. Из этого числа 82,2 % заболеваний было выявлено на ранних стадиях опухолевого процесса. Лечение по радикальной программе получили 75,2 % женщин. Пятилетняя выживаемость пациенток с впервые уста-новленным диагнозом РМЖ в 2009 г. составила 76 %, среди женщин с I и II стадиями заболевания -85,6 %, с III стадией -58,6 %, с IV стадией -14,1 %. Смерт-ность от злокачественных новообразований молочной железы составила в 2014 г. 21 на 100 тыс. женщин [1].Таким образом, лечение первичного РМЖ является сложной и не окончательно решенной на сегодняшний день проблемой. На современном этапе план лечебных мероприятий включает, как правило, несколько компо-нентов: хирургическое лечение, лучевое лечение, ХТ, гормонотерапию в случае положительных гормональ-ных рецепторов в опухоли и таргетную терапию при экспрессии опухолью эпидермального фактора ро-ста 2-го типа (НЕR-2 / neu).Однако факторы, приводящие к развитию отда-ленных метастазов, до сих пор недостаточно изучены.

show abstract

Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast

Cited by 6 publications

References 16 publications

Metastases from Neuroendocrine Tumors to the Breast Are More Common than Previously Thought. A Diagnostic Pitfall?

Metastases from Neuroendocrine Tumors to the Breast Are More Common than Previously Thought. A Diagnostic Pitfall?

Cytokeratin 7 negative invasive breast carcinoma: clinicopathological and immunohistochemical analysis of 14 cases with clinical follow-up

Treatment of patients with bone marrow metastases: the present state of the problem

Contact Info

Product

Resources

About